Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-24T08:57:15.220Z Has data issue: false hasContentIssue false
  • English
  • Français

Current issues in monoamine oxidase inhibitor treatment

Published online by Cambridge University Press:  13 June 2014

Sinead O'Brien  and
Patrick McKeon
Patrick McKeon
Affiliation:
Depression Research Unit, St. Patrick's Hospital, Dublin.
Get access Rights & Permissions [Opens in a new window]

Abstract

Interest in the monoamine oxidase (MAO) inhibitors has been revived over the past fifteen years since the publication of studies and reviews which argue their relative safety and efficacy in certain patient subgroups. The authors conclude that there is a continuing role for the MAO inhibitors in treating atypical depressive illness and panic disorders. Careful selection of patients to be commenced on MAO inhibitor treatment is advised. When prescribed alone or in combination with lithium there is evidence to support a usefulness for MAO inhibitors in depression resistant to the tricyclic antidepressants. Their efficacy in the depressed phase of bipolar affective disorder or in combination with the tricyclic antidepressants remains unproven. The risk of anaesthesia while a patient is receiving MAO inhibitor treatment may be less than heretofore believed. There is realistic hope of finding among the short-acting selective MAO inhibitors an effective antidepressant which is also free from tyramine related effects. With the increasing difficulties of evaluating new drugs on account of ethical and governmental constraints, it may however be some time before the preliminary hopeful findings can be substantiated in larger groups of patients.

Keywords

Monoamine oxidase inhibitorsAtypical depressionResistant depressionCombined antidepressantsSelective MAO inhibitorsReversible MAO inhibitors.
Type
Review Articles
Information
Irish Journal of Psychological Medicine , Volume 7 , Issue 2 , September 1990 , pp. 159 - 167
Copyright
Copyright © Cambridge University Press 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.British Medical Research Council. Clinical trial of the treatment of depressive illness. Br Med J 1965; 1: 881–886.CrossRefGoogle Scholar
2.Raskin, A, Schulterbrandt, J, Reatig, N, Crook, T, Odle, D. Depression subtypes and response to phenelzine, diazepam, and a placebo. Arch Gen Psychiatry 1974; 30: 66–75.CrossRefGoogle ScholarPubMed
3.Rosenblum, LE, Korn, RJ, Zimmerman, HJ. Hepatocellular jaundice as a complication of iproniazid therapy. Arch Intern Med 1960; 205: 583.CrossRefGoogle Scholar
4.Robinson, DS, Nies, A, Ravaris, L, Lambourn, KR. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch Gen Psychiatry 1973; 29: 407–13.CrossRefGoogle ScholarPubMed
5.Ravaris, CL, Nies, A, Robinson, DS, et al.A multiple-dose controlled study of phenelzine in depressive-anxiety states. Arch Gen Psychiatry 1976; 33: 347–50.CrossRefGoogle Scholar
6.Johnstone, EC, Marsh, W. Acetylator status and response to phenelzine in depressed patients. Lancet 1973; 1: 567–70.CrossRefGoogle ScholarPubMed
7.Janicak, PG, Ghanshyam, NP, Davis, JM, Boshes, R, Bresnahan, D, Sharma, R. Response of psychotic and nonpsychotic depression to phenelzine. Am J Psychiatry 1988; 145: 93–5.Google ScholarPubMed
8.Murphy, DL, Garrick, NA, Aulakh, CS. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psychiatry 1984; 45: 37–43.Google ScholarPubMed
9.Tyrer, P. Clinical use of monoamine oxidase inhibitors. In: Paykel, ES, Coppen, A, eds. Psychopharmacology of affective disorders. Oxford: Oxford University Press, 1979.Google Scholar
10.Paykel, ES, White, JL. A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 1989; 155 (suppl. 6): 9–17.CrossRefGoogle Scholar
11.Richmond, P, Roberts, A. A comparative trial of imipramine, amitriptyline, isocarboxazid and tranylcypromine in out-patient depressive illness. Br J Psychiatry 1964; 110: 846–50.CrossRefGoogle ScholarPubMed
12.Himmelhoch, J, Fuchs, C, Symons, B. A double-blind study of tranylcypromine treatment of major anergic depression. J. Nerv Ment Dis 1982; 170: 628–34.CrossRefGoogle ScholarPubMed
13.McGrath, P, Quitkin, F, Harrison, W, Stewart, J. Treatment of melancholia with tranylcypromine. Am J Psychiatry 1984; 141: 2, 288–89.Google ScholarPubMed
14.Davidson, JR, Miller, RD, Craig, D, et al.Atypical depression. Arch Gen Psychiatry 1982; 39: 527–34.CrossRefGoogle ScholarPubMed
15.Paykel, ES, Rowan, PR, Rao, BM and Bhat, A. Atypical depression: nosology and response to antidepressants. In: Clayton, PJ, Barrett, JE, eds. Treatment of depression: old controversies and new approaches. New York: Raven Press, 1983.Google Scholar
16.Liebowitz, MR, Quitkin, FM, Stewart, JW, et al.Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129–37.CrossRefGoogle ScholarPubMed
17.Quitkin, FM, Stewart, DJW, McGrath, PJ, Liebowitz, MR, Harrison, WM, Tricamo, E, et al.Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988, 145: 306–11.Google ScholarPubMed
18.White, K, Razani, J, Cadow, B, et al.Tranylcypromine vs nortriptyline vs placebo in depressed outpatients; a controlled trial. Psychopharmacology 1984; 82: 258–62.CrossRefGoogle ScholarPubMed
19.White, K, White, J. Tranylcypromine: patterns and predictors of response. J. Clin Psychiatry 1986; 47: 380–2.Google ScholarPubMed
20.Ayd, F. Treatment-resistant depression: therapeutic strategies. In: Ayd, F, et al.Affective disorders reassessed. Baltimore: Ayd Medical Communications, 1983.Google Scholar
21.McGrath, P, Stewart, J, Harrison, W, Quitkin, F. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987; 23: 169–72.Google ScholarPubMed
22.Price, L, Charney, D, Heninger, G. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985; 142: 619–23.Google ScholarPubMed
23.Tariot, PN, Murphy, D, Sunderland, T, et al.Rapid antidepressant effect of addition of lithium to tranylcypromine. J Clin Psychopharmacol 1986; 6: 165–7.CrossRefGoogle ScholarPubMed
24.Stancer, H. letter. Am J Psychiatry 1979; 136: 727.Google Scholar
25.Pare, CMB. Potentiation of monoamine oxidase inhibitors by tryptophan. Lancet 1963; 2: 527–8.CrossRefGoogle ScholarPubMed
26.Coppen, A, Shaw, DM, Farrell, JP. Potentiation of the antidepressant effect of a monoamine oxidase inhibitor by tryptophan. Lancet 1963; 1: 79–81.CrossRefGoogle ScholarPubMed
27.Eccleston, D. Conference on Resistant Depression. London: Royal Society of Medicine, 1986.Google Scholar
28.Sargent, W, Dally, PD. Treatment of anxiety states by antidepressant drugs. Br Med J 1962; 1: 6.CrossRefGoogle Scholar
29.Pohl, R, Berchou, R, Rainey, J. Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia. J Clin Psychopharmacol 1982; 2: 399–407.CrossRefGoogle ScholarPubMed
30.Blier, P, de Montigny, C. Serotonergic but not noradrenergic neurons in rat CNS adapt to long-term treatment with MAOI's. Neuroscience 1985; 16: 949–55.CrossRefGoogle Scholar
31.Tyrer, P, Candy, J, Kelly, D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 1973; 32: 237–54.CrossRefGoogle ScholarPubMed
32.Sheehan, DV, Ballenger, JC, Jacobsen, G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51–59.CrossRefGoogle ScholarPubMed
33.Solyom, L, Heseltine, G. McClure, D, Solyom, C, Ledwidge, B, Steinberg, G. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Can Psych Ass J 1973; 18: 25–32.Google ScholarPubMed
34.Liebowitz, MR, Fyer, AJ, Gorman, JM, et al.Phenelzine in social phobia. J Clin Psychopharmacol 1986; 6: 93–8.CrossRefGoogle ScholarPubMed
35.Pare, CMB. The present status of monoamine oxidase inhibitors. Br J Psychiatry 1985; 146: 576–84.CrossRefGoogle ScholarPubMed
36.Rabkin, J, Quitkin, F, McGrath, P, Harrison, W, Tricamo, E. Adverse reactions to monoamine oxidase inhibitors. Part II: Treatment correlates and clinical management. J Clin Psychopharmacol 1985; 5: 2–9.CrossRefGoogle ScholarPubMed
37.Massey Stewart, M. MAOIs and food - fact and fiction. Adverse Drug Reaction Bulletin 1976; 58: 200–3.CrossRefGoogle Scholar
38.Folks, DG. Monoamine oxidase inhibitors: reappraisal of dietary considerations. J Clin Psychopharmacol 1983; 4: 249–52.Google Scholar
39.Blackwell, B, Marley, E, Price, J, Taylor, D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967; 113: 349–65.CrossRefGoogle ScholarPubMed
40.Raskin, A, Schulterbrandt, J, Reatig, N, Crook, T, Odle, D. Depression subtypes and response to phenelzine, diazepam and a placebo. Arch Gen Psychiatry 1974; 30: 66–75.CrossRefGoogle ScholarPubMed
41.Neil, J, Licata, S, May, S, Himmelhoch, J. Dietary noncompliance during treatment with tranylcypromine. J Clin Psychiatry 1979; 40: 33–7.Google Scholar
42.Kronig, MH, Roose, SP, Walsh, BT, et al.Blood pressure effects of phenelzine. J Clin Psychopharmacol 1983; 3: 307–10.CrossRefGoogle ScholarPubMed
43.O'Brien, S, McKeon, P. The MAOI, tranylcypromine – prescribed singly and in combination with a tricyclic antidepressant. Abstracts of Royal College of Psychiatrists Autumn Quarterly Meeting, 1988.Google Scholar
44.McDaniel, KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol 1986; 9: 207–34.CrossRefGoogle ScholarPubMed
45.Pickar, D, Murphy, D, Cohen, R, Campbell, I, Lipper, S. Selective and nonselective monoamine oxidase inhibitors. Arch Gen Psychiatry 1982; 39: 535–40.CrossRefGoogle ScholarPubMed
46.Dilsaver, SC. Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand 1988; 78: 1–7.CrossRefGoogle ScholarPubMed
47.Liskin, B, Roose, SP, Walsh, BT, Jackson, WK. Acute psychosis following phenelzine discontinuation. J Clin Psychopharmacol 1985; 5: 46–7.CrossRefGoogle ScholarPubMed
48.Frankel, DA, Raskin, DE. Psychosis following phenelzine discontinuation. J Clin Psychopharmacol 1985; 5: 360.Google Scholar
49.Mann, J. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 1983; 3: 363–6.CrossRefGoogle ScholarPubMed
50.Le Gassicke, J. Letter. Lancet 1963; 270.Google Scholar
51.Westermeyer, J. Addiction to tranylcypromine (Parnate); a case report. Am J Drug Alcohol Abuse 1989; 15: 345–50.CrossRefGoogle ScholarPubMed
52.Ben-Arie, O, George, G. A case of tranylcypromine (Parnate) addiction. Br J Psychiatry 1979; 135: 273–4.CrossRefGoogle ScholarPubMed
53.Griffin, N, Draper, R, Webb, M. Addiction to tranylcypromine. Br Med J 1981; 283: 346.CrossRefGoogle ScholarPubMed
54.Zimmerman, HJ, Ishak, KG. The hepatic injury of monoamine oxidase inhibitors. J Clin Psychopharmacol 1987; 7: 211–3.Google ScholarPubMed
55.Zimmerman, HJ. Hepatoxicity: the adverse effects of drugs and other chemicals on the liver, chap 18. New York: Appleton-Century-Crofts, 1978.Google Scholar
56.Shepherd, JT, Whiting, B. (letter) Lancet 1974; 2: 1021.CrossRefGoogle Scholar
57.Matter, BJ, et al. (letter) Arch Intern Med 1976; 116: 18.CrossRefGoogle Scholar
58.Quitkin, F, McGrath, P, Liebowitz, R, Stewart, J, Howard, A. Monoamine oxidase inhibitors in bipolar endogenous depressives. J Clin Psychopharmacol 1981; 1: 70–4.CrossRefGoogle ScholarPubMed
59.Young, JPR, Lader, MH, Hughes, WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979; iv: 1315–7.CrossRefGoogle Scholar
60.Davidson, J, McLeod, M, Law-Yone, B, Linnoila, M. A comparison of electroconvulsive therapy and combined phenelzine-amitripyline in refractory depression. Arch Gen Psychiatry 1978; 35: 639–42.CrossRefGoogle ScholarPubMed
61.Razani, J, White, K, White, J, Simpson, G, Sloane, R, Rebal, R, Palmer, R. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. Arch Gen Psychiatry 1983; 40: 657–61.CrossRefGoogle ScholarPubMed
62.White, K, Simpson, G. Combined MAOI-tricyclic antidepressant treatment; a re-evaluation. J Clin Psychopharmacol 1981; 1: 264–82.CrossRefGoogle Scholar
63.Ayd, F. Guidelines for safe and effective use of combined tricyclic-MAOI therapy. Int Drug Ther Newsletter 1979; 14(2): 7–8.Google Scholar
64.Pare, CMB, Hallstrom, C, Kline, N, Cooper, TB. Will amitriptyline prevent the “cheese” reaction on monoamine oxidase inhibitors? Lancet 1982; 2(8291): 183–6.CrossRefGoogle ScholarPubMed
65.Remick, R, Jewesson, P, Ford, RW. Monoamine oxidase inhibitors in general aneasthesia: a re-evaluation. Convulsive Ther 1987; 3: 196–203.Google Scholar
66.El-Ganzouri, AR, Ivankovich, AD, Braverman, B, McCarthy, R. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anaesth Analg 1985; 64: 592–6.CrossRefGoogle ScholarPubMed
67.Herd, J. A new antidepressant – M and B 9302. A pilot study and double-blind controlled trial. Clinical trials 1969; 6: 219–25.Google Scholar
68.Wheatley, D. Comparative trial of a new monoamine oxidase inhibitor in depression. Br J Psychiatry 1970; 117: 547.CrossRefGoogle ScholarPubMed
69.Lipper, S, Murphy, DL, Slater, S, Buchsbaum, MS. Comparative behavioural effects of clorgyline and pargyline in preliminary evaluation. Psychopharmacol (Berlin) 1979; 62: 123–8.CrossRefGoogle ScholarPubMed
70.Murphy, D, Sunderland, T, Garrick, N, Aulakh, C, Cohen, R. Selective amine oxidase inhibitors: basic to clinical studies and back. Clin Pharm Psych 1987; 3: 135–46.Google ScholarPubMed
71.Simpson, GM, De Leon, J. Tyramine and new monoamine oxidase inhibitor drugs. Br J Psychiatry 1989; 115 (suppl. 6): 32–7.CrossRefGoogle Scholar
72.Potter, W, Murphy, D, Wehr, T, Linnoila, M, Goodwin, F. Clorgyline: a new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiatry 1982; 39: 505–10.CrossRefGoogle ScholarPubMed
73.Mendlewicz, J, Youdim, MB. L-Deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double-blind evaluation. Br J Psychiatry 1984; 142: 508–11.CrossRefGoogle Scholar
74.Aarons, SF, Mann, JJ, Frances, A, Kocsis, J, Young, RC. Antidepressant effect of L-deprenyl: relative contribution of MAO A versus MAO B inhibition. Abstract, Collegium International, Neuro-Psycho-pharmacologium 14th C.I.N.P. Congress, Florence, 06 1984.Google Scholar
75.Amrein, R, Allen, SR, Guentert, TW, et al.The pharmacology of reversible monoamine oxidase inhibitors. Br J Psychiatry 1989; 155 (suppl. 6): 66–71.CrossRefGoogle Scholar
76.Norman, TR. A controlled study of a specific MAO A reversible inhibitor (Roll-1163) and amitriptyline in depressive illness. J Affect Disord 1985; 8: 29–35.CrossRefGoogle ScholarPubMed
77.Versiani, M, Oggero, U, Alterwain, P, et al.A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry 1989; 155 (suppl. 6): 72–7.CrossRefGoogle Scholar